The chairman and CEO of the Genzyme Corporation, one of the country's top five biotechnology firms, has received a phone call requesting a meeting with the cofounder and principal of a large activist investment fund that now has a 2.6% stake in his company. Before meeting with him, the CEO is aware that he needs a strategy for dealing with this “activist” investor with a track record of forcing out CEOs.
CitationDownload as .RIS
University of Virginia Darden School Foundation
Copyright © 2011 by the University of Virginia Darden School Foundation, Charlottesville, VA. All rights reserved.